Form 4: PDS Biotech CSO Granted 150,000 Stock Options

PDS Biotechnology's Chief Scientific Officer, Gregory Conn, was granted 150,000 employee stock options with an exercise price of $0.98, vesting over four years.

Summary

• Gregory Conn, Chief Scientific Officer of PDS Biotechnology Corp (PDSB), was granted 150,000 employee stock options.
• The options have an exercise price of $0.98 per share.
• The transaction date for this grant was January 12, 2026.
• The options will vest over four years, with 25% becoming exercisable on January 12, 2027, and the remaining 75% vesting in 36 equal monthly installments thereafter.
• Vesting is contingent upon Mr. Conn's continued service to the Issuer.
• The options expire on January 12, 2036.
• Following this transaction, Mr. Conn beneficially owns 150,000 derivative securities.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive for aligning executive incentives with long-term company performance, reflecting confidence in future growth and encouraging executive retention.

Positives

• The grant of 150,000 employee stock options to the Chief Scientific Officer, Gregory Conn, aligns his long-term incentives with shareholder interests.
• The four-year vesting schedule encourages executive retention and sustained focus on the company's strategic goals.

Risks

• No specific risks are mentioned in this Form 4 filing, which primarily discloses an executive compensation grant.

Future Outlook

The vesting schedule of the granted options implies an expectation of Gregory Conn's continued service to PDS Biotechnology Corp for at least the next four years, aligning his long-term compensation with the company's future performance.

Industry Context

StockSavvy.ai notes that stock option grants are a common form of executive compensation in the biotechnology industry, serving to align management incentives with shareholder value creation and encourage long-term commitment to the company's strategic objectives.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages across the biotechnology sector, similar to practices observed at companies like Moderna, BioNTech, or Regeneron, which use equity incentives to attract and retain key scientific and executive talent.
• The four-year vesting schedule is typical for such grants, providing a balance between immediate incentive and long-term retention, consistent with industry benchmarks for executive equity awards.

Stakeholder Impact

• Shareholders may benefit from the increased alignment of executive incentives with the company's stock performance, potentially leading to enhanced long-term value creation.
• Employees may view this as a positive signal regarding executive commitment and the company's future prospects.

Next Steps

• Gregory Conn's continued service to the Issuer is required for the options to vest according to the established schedule.

Key Dates

Keywords

PDSB, PDS Biotechnology, stock option, Form 4, insider transaction, executive compensation, equity grant